RESUMEN
In this study, the authors report their experience with latanoprost after a year's treatment of patients with various forms of glaucoma at various stages of progression. The new drug was associated also with different beta-blockers. The case file reported includes 30 eyes of 18 patients treated with latanoprost once a day in the evening. Follow-up varied from 6 months to 1 year. Except for 2 patients (3 eyes) receiving only latanoprost therapy, all the others received latanoprost in association with their on-going therapy. Results are equivalent to those described in the literature. The authors also consider the results in two groups; chronic simple glaucoma and other forms of glaucoma. From their own experience and from what is reported in the literature, the authors conclude by stressing the pressure reducing efficacy of this drug.
Asunto(s)
Glaucoma de Ángulo Abierto/tratamiento farmacológico , Presión Intraocular/efectos de los fármacos , Prostaglandinas F Sintéticas/uso terapéutico , Sistema Nervioso Simpático/efectos de los fármacos , Antagonistas Adrenérgicos beta/administración & dosificación , Antagonistas Adrenérgicos beta/uso terapéutico , Adulto , Anciano , Enfermedad Crónica , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Glaucoma de Ángulo Abierto/fisiopatología , Humanos , Latanoprost , Masculino , Persona de Mediana Edad , Hipertensión Ocular/tratamiento farmacológico , Hipertensión Ocular/fisiopatología , Soluciones Oftálmicas , Parasimpaticomiméticos/administración & dosificación , Parasimpaticomiméticos/uso terapéutico , Prostaglandinas F Sintéticas/administración & dosificación , Resultado del Tratamiento , Agudeza Visual/efectos de los fármacosRESUMEN
Two cases of non-familial hemiplegic migraine are described. Naloxone reversed the neurological deficits accompanying attacks, whereas the pain was uninfluenced. The possibility that the opiate-antagonist naloxone facilitates regression of neurological symptoms associated with migraine attacks in general is voiced.
Asunto(s)
Hemiplejía/tratamiento farmacológico , Trastornos Migrañosos/tratamiento farmacológico , Naloxona/uso terapéutico , Adulto , Femenino , Humanos , MasculinoRESUMEN
The Authors, starting with the hypothesis that could exist a correlation between the opiate withdrawal and the migraine crisis, used the naloxone, opiate pure antagonist, in order to induced the migraine crisis. 30 patients affected by migraine were studied; naloxone was administered acutely (2 mg e.v.) during the asintomatic period. The naloxone administration never caused the migraine crisis. The patients didn't complain variations regarding the psycho-physical status or the monitored clinical parameters.
Asunto(s)
Trastornos Migrañosos/inducido químicamente , Naloxona , Síndrome de Abstinencia a Sustancias , Adolescente , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trastornos Migrañosos/etiología , NarcóticosRESUMEN
The authors evaluated the efficacy of a DHE methanesulphonate for migraine attacks and its tolerability on liver, gallbladder and cardiovascular system functions. Twenty-eight patients affected by migraine were studied. They were withdrawn from preventive therapy for at least one month and treated for three months. The drug showed a good efficacy with a statistical significant reduction of severity and duration of attacks. No variation of the biochemical and morphological parameters of liver, gallbladder and cardiovascular function were found throughout the treatment.